Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

NCT07643623 is registered in ClinicalTrials.gov with Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. as lead sponsor.

NCT NCT07643623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07643623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 31, 2026
Completion date
December 31, 2031
Enrollment
720 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable gastric/gastroesophageal junction adenocarcinoma